The Safety Rates Drug Report

Member Login
2004.Q1    2004.Q2    2004.Q3    2004.Q4    2005.Q1    2005.Q2    2005.Q3    2005.Q4    2006.Q1    2006.Q2    2006.Q3    2006.Q4    2007.Q1    2007.Q2    2007.Q3    2007.Q4    2008.Q1    2008.Q2    2008.Q3    2008.Q4    2009.Q1    2009.Q2    2009.Q3    2009.Q4    2010.Q1    2010.Q2    2010.Q3    2010.Q4    2011.Q1    2011.Q2    2011.Q3    2011.Q4    2012.Q1    2012.Q2    2012.Q3    2012.Q4    2013.Q1    2013.Q2    2013.Q3    2013.Q4    2014.Q1    2014.Q2    2014.Q3    2014.Q4    2015.Q1    2015.Q2    2015.Q3    2015.Q4    2016.Q1    2016.Q2    2016.Q3   

Drug     Injury     Quarter    

Person who experienced the adverse event (patient)

Event ID CASEID CASEVERSION I F COD EVENT DT MFR DT INIT FDA DT FDA DT REPT COD AUTH NUM MFR NUM MFR SNDR LIT REF AGE AGE COD AGE GRP GNDR COD E SUB WT WT COD REPT DT TO MFR OCCP COD REPORTER COUNTRY OCCR COUNTRY
961100314 9611003 14 F 20140109 20160627 20131009 20160706 EXP US-GLAXOSMITHKLINE-A1044643A GLAXOSMITHKLINE 49.24 YR F Y 48.60000 KG 20160706 CN US US

Drug(s) used by person

Event ID CASEID DRUG SEQ ROLE COD DRUGNAME PROD AI VAL VBM ROUTE DOSE VBM CUM DOSE CHR CUM DOSE UNIT DECHAL RECHAL LOT NUM EXP DT NDA NUM DOSE AMT DOSE UNIT DOSE FORM DOSE FREQ
961100314 9611003 1 PS FLOLAN EPOPROSTENOL SODIUM 1 Intravenous (not otherwise specified) DOSE 76 NG/KG/MIN, CONCENTRATION 75,000 NG/ML, PUMP RATE 79 ML/DAY, VIAL STRENGTH 1.5 MGREDUCED[...] P508 20444 POWDER FOR INFUSION
961100314 9611003 2 SS FLOLAN EPOPROSTENOL SODIUM 1 UNK R271A 20444 POWDER FOR INFUSION
961100314 9611003 3 SS FLOLAN EPOPROSTENOL SODIUM 1 Intravenous (not otherwise specified) 71 NG/KG/MIN CONTINUOUS; CONCENTRATION: 75,000 NG/ML; PUMP RATE: 74 ML/DAY; VIAL STRENGTH: 1.5 MG T366 20444 POWDER FOR INFUSION
961100314 9611003 4 SS FLOLAN EPOPROSTENOL SODIUM 1 Intravenous (not otherwise specified) UNK, CO U893 20444 POWDER FOR INFUSION
961100314 9611003 5 SS FLOLAN EPOPROSTENOL SODIUM 1 Intravenous (not otherwise specified) UNK, CO U893 20444 POWDER FOR INFUSION
961100314 9611003 6 SS FLOLAN EPOPROSTENOL SODIUM 1 Intravenous (not otherwise specified) 71 DF, CO V926 20444 71 DF POWDER FOR INFUSION
961100314 9611003 7 SS FLOLAN EPOPROSTENOL SODIUM 1 22 DF, CO V926 20444 22 DF POWDER FOR INFUSION
961100314 9611003 8 SS FLOLAN EPOPROSTENOL SODIUM 1 71 DF, CO V926 20444 71 DF POWDER FOR INFUSION
961100314 9611003 9 SS FLOLAN EPOPROSTENOL SODIUM 1 Intravenous (not otherwise specified) 71 DF, CO V926 20444 71 DF POWDER FOR INFUSION
961100314 9611003 10 C ADCIRCA TADALAFIL 1 U 0
961100314 9611003 11 C LETAIRIS AMBRISENTAN 1 U 0
961100314 9611003 12 C WARFARIN WARFARIN 1 U 0
961100314 9611003 13 C COUMADIN WARFARIN SODIUM 1 U 0

Indications of drugs used

Event ID CASEID INDI DRUG SEQ INDI PT
961100314 9611003 1 Pulmonary arterial hypertension

Outcome of event

Event ID CASEID OUTC COD
961100314 9611003 DE
961100314 9611003 HO
961100314 9611003 OT

Reactions reported

Event ID CASEID DRUG REC ACT PT
961100314 9611003 Bronchial haemorrhage
961100314 9611003 Death
961100314 9611003 Diarrhoea
961100314 9611003 Headache
961100314 9611003 Hospitalisation
961100314 9611003 Incorrect dose administered
961100314 9611003 Living in residential institution
961100314 9611003 Mechanical ventilation
961100314 9611003 Nasopharyngitis
961100314 9611003 Urinary tract infection
961100314 9611003 Vascular injury
961100314 9611003 Weight decreased

Reporting Sources (this data is often not reported and may therefore be missing here)

no results found

Therapies reported

Event ID CASEID DSG DRUG SEQ START DT END DT DUR DUR COD
961100314 9611003 1 20000920 0
961100314 9611003 3 20000920 0
961100314 9611003 4 20000920 0
961100314 9611003 5 20000920 0
961100314 9611003 6 20000920 0
961100314 9611003 7 20000929 0
961100314 9611003 8 20000929 0
961100314 9611003 9 20000920 0